These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38115178)

  • 1. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
    Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
    Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
    Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
    Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
    Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
    Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
    Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
    Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
    Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
    Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
    Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
    Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
    Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
    Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
    Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
    Front Immunol; 2022; 13():885424. PubMed ID: 35837391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zolbetuximab: First Approval.
    Keam SJ
    Drugs; 2024 Aug; 84(8):977-983. PubMed ID: 38967717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
    Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
    J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer.
    Zeng Y; Lockhart AC; Jin RU
    Expert Opin Drug Discov; 2024 Aug; 19(8):873-886. PubMed ID: 38919123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications.
    Wang Y; Ma L; Kuang Z; Li D; Yang J; Liu Y; Zhang L; Li Z; Li Q
    Mol Pharm; 2024 Aug; 21(8):3838-3847. PubMed ID: 38949095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
    Kubota Y; Shitara K
    Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
    O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
    Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer.
    Matsuishi A; Nakajima S; Saito M; Saito K; Fukai S; Tsumuraya H; Kanoda R; Kikuchi T; Nirei A; Kaneta A; Okayama H; Mimura K; Hanayama H; Sakamoto W; Momma T; Saze Z; Kono K
    Sci Rep; 2024 Aug; 14(1):17916. PubMed ID: 39095563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
    Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
    BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
    Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
    Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.